Therefore, we treated cancer cells with the CCL2 ligand (100–300 ng/ml) for 24–48 h and found that MUC5AC expression was increased in A549-BrM cells in a dose-dependent manner (Fig. 5e). Here, MUC5AC is linked to cancer.